Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Enlivex Therapeutics stock
Learn how to easily invest in Enlivex Therapeutics stock.
Enlivex Therapeutics Ltd is a biotechnology business based in the US. Enlivex Therapeutics shares (ENLV) are listed on the NASDAQ and all prices are listed in US Dollars. Enlivex Therapeutics employs 50 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Enlivex Therapeutics
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – ENLV – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Enlivex Therapeutics stock price (NASDAQ: ENLV)Use our graph to track the performance of ENLV stocks over time.
Enlivex Therapeutics shares at a glance
|Latest market close||$5.80|
|52-week range||$5.55 - $29.40|
|50-day moving average||$6.92|
|200-day moving average||$9.04|
|Wall St. target price||$33.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.92|
Buy Enlivex Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Enlivex Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Enlivex Therapeutics price performance over time
|1 week (2022-01-13)||0.35%|
|1 month (2021-12-20)||-8.23%|
|3 months (2021-10-20)||-34.39%|
|6 months (2021-07-20)||-22.04%|
|1 year (2021-01-20)||-51.67%|
|2 years (2020-01-17)||-35.04%|
|3 years (2019-01-18)||460.44%|
|5 years (2017-01-20)||400.00%|
Enlivex Therapeutics financials
|Gross profit TTM||$0|
|Return on assets TTM||-14.42%|
|Return on equity TTM||-26.76%|
|Market capitalisation||$107.6 million|
TTM: trailing 12 months
Enlivex Therapeutics share dividends
We're not expecting Enlivex Therapeutics to pay a dividend over the next 12 months.
Have Enlivex Therapeutics's shares ever split?
Enlivex Therapeutics's shares were split on a 1:8 basis on 5 March 2019. So if you had owned 8 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Enlivex Therapeutics shares – just the quantity. However, indirectly, the new 700% higher share price could have impacted the market appetite for Enlivex Therapeutics shares which in turn could have impacted Enlivex Therapeutics's share price.
Enlivex Therapeutics share price volatility
Over the last 12 months, Enlivex Therapeutics's shares have ranged in value from as little as $5.55 up to $29.4. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Enlivex Therapeutics's is 0.4608. This would suggest that Enlivex Therapeutics's shares are less volatile than average (for this exchange).
Enlivex Therapeutics overview
Enlivex Therapeutics Ltd. operates as a clinical stage immunotherapy company. It is developing Allocetra, an off-the-shelf cell therapy designed to reprogram macrophages into homeostatic state. Resetting non-homeostatic macrophages into homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. Diseases, such as solid cancers, sepsis, COVID-19, and others reprogram macrophages out of homeostatic state. Its Allocetra has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents. The company has a research collaboration with Yale Cancer Center for the assessment of Allocetra to enhance the activity of checkpoint inhibitors in solid tumors.
Enlivex Therapeutics in the news
Microsoft's $68.7 billion deal for Activision once again shows big tech's dominance over legacy media
Supreme Court vaccine mandate ruling won't bar companies from demanding Covid shots for workers — Biden vows to advocate for that
Two of Sen. Kyrsten Sinema's former aides have lobbied for corporate giants looking to influence Joe Biden's agenda
Frequently asked questionsWhat percentage of Enlivex Therapeutics is owned by insiders or institutions?
Currently 12.398% of Enlivex Therapeutics shares are held by insiders and 12.377% by institutions. How many people work for Enlivex Therapeutics?
Latest data suggests 50 work at Enlivex Therapeutics. When does the fiscal year end for Enlivex Therapeutics?
Enlivex Therapeutics's fiscal year ends in December. Where is Enlivex Therapeutics based?
Enlivex Therapeutics's address is: 14 Einstein Street, Ness Ziona, Israel, 7403618 What is Enlivex Therapeutics's ISIN number?
Enlivex Therapeutics's international securities identification number is: IL0011319527 What is Enlivex Therapeutics's CUSIP number?
Enlivex Therapeutics's Committee on Uniform Securities Identification Procedures number is: M20156101
More guides on Finder
Donut savings review
Donut earns up to 10% APY, but you must have an iOS device.
Covid test stocks
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Is Berkshire Hathaway the next $1 trillion stock?
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
How to buy Affinia Therapeutics (AFTX) stock when it goes public
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
How to buy Austin Gold (AUST) stock when it goes public
Everything we know about the Austin Gold IPO, plus information on how to buy in.
How to buy VinFast stock when it goes public
Everything we know about the VinFast IPO, plus information on how to buy in.
NFT-funded LinksDAO moves $10.5 million closer to buying a golf course
Creating a golf club is a thus-far unique application of NFTs, and another step forward for the decentralized economy.
How to buy Nexalin Technology (NXL) stock when it goes public
Everything we know about the Nexalin Technology IPO, plus information on how to buy in.
How to buy Specialty Building Products (SBP) stock when it goes public
Everything we know about the Specialty Building Products IPO, plus information on how to buy in.
How to buy HeartCore Enterprises (HTCR) stock when it goes public
Everything we know about the HeartCore Enterprises IPO, plus information on how to buy in.
Ask an Expert